KRAS and gastric cancer: Among the predicted genes, the most promising candidates for cross-cancer therapies are ERBB2/Her2, FGFR1, IDH1, and KRAS because our analysis finds consistent protein profile changes across histotypes (ERBB2/Her2 among others breast cancer – gastric cancer, FGFR1: breast cancer – lung adenocarcinoma, IDH1: low-grade glioma – glioblastoma and KRAS: lung adenocarcinoma – endometrial carcinoma) for these genes.